The two faces of myeloproliferative neoplasms: Molecular events underlying lymphoid transformation

Holroyd, Ailsa K.; Cross, Nicholas C.P.; Macdonald, Donald

doi:10.1016/j.leukres.2011.05.037

Cited by 11 publications

(17 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common lymphoid neoplasm is T lymphoblastic lymphoma. The concurrence of myeloid and lymphoid malignancies was reported both in human cases and animal models [2]. …”

Section: Discussionmentioning

confidence: 99%

“…In such a classification system, all cases of concurrent myeloid neoplasms and T lymphomblastic lymphoma, including the present case, belong to the same category. While most cases of this entity presented with MPNs, the genetic aberrations have a wide spectrum of differentiations, including eosinophilia, myelodysplastic syndrome, chronic myelomonocytic leukemia, AML, B or T cell acute lymphoblastic leukemia, T lymphoblastic lymphoma, and disorders with mast cell proliferation [2]. Most cases with PDGFRA gene rearrangements manifest as MPNs, usually chronic eosinophilic leukemia.…”

Section: Discussionmentioning

confidence: 99%

“…While these reports revealed it is not uncommon for PDGFRA and FGFR1 genetically rearranged cells to differentiate into lymphoid neoplasms, hematologic diseases bearing PDGFRB mutations are rare [2,5]. The two largest series reported in literature included 22 and 9 cases respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Although most cases presented with myeloproliferative neoplasm (MPN) and eosinophilia, this group of diseases was known to develop into multiple lineages of hematologic malignancies both in animal models and human cases [2]. In humans, concurrent myeloid neoplasms and T lymphoblastic lymphoma have been reported with FIP1L1-PDGFRA fusion genes [3,4] but not with any PDGFRB rearranged genes.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes

et al. 2012

View full text Add to dashboard Cite

Concurrent hematologic malignancies are relatively rare. We encountered a case of concurrent acute myeloid leukemia (AML) and T lymphoblastic lymphoma. The bone marrow chromosome analysis showed the karyotype 46, XY, t(5;12)(q33;p13), which indicated presence of PDGFRB gene translocations. Therefore, this disease belongs to the new WHO category of myeloid and lymphoid neoplasms with abnormalities in PDGFRA, PDGFRB and FGFR1 genes. Although such genetic mutations are prone to multi-lineage differentiation, the present case is in fact the first report of concurrent AML and T lymphoblastic lymphoma involving PDGFRB mutations. The patient was treated with cytarabine and daunomycin in combination with high dose dexamethasone. Allogeneic stem cell transplantation was performed after successful remission induction for both entities. The patient eventually died of chronic graft-versus-host-disease related infection. Based on such an experience, we suggest the decision of stem cell transplantation should be weighed carefully against the risks, especially when tyrosine kinase inhibitors are safe and potentially effective in dealing with such entities.

show abstract

“…The most common lymphoid neoplasm is T lymphoblastic lymphoma. The concurrence of myeloid and lymphoid malignancies was reported both in human cases and animal models [2]. …”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Manyothertranslocationshavebeenreportedthatareapparently unique, but there are at least 4 recurrent breakpoint clusters at 4q11-12, 5q31-33, 8p11-12, and 9p24. Molecular analysis has shown that these translocations involve the TK genesPDGFRA,PDGFRB,FGFR1,andJAK2,respectively [48][49][50] (fig.2).…”

Section: Translating the Success Of Imatinib To Other Malignanciesmentioning

confidence: 99%

Imatinib and Beyond – Targeting Activated Tyrosine Kinases in Myeloproliferative Disorders

Hochhaus

Reiter²,

Ernst

et al. 2012

Onkologie

View full text Add to dashboard Cite

Tyrosine kinases (TKs) play a major role in cellular signal transduction. Deregulated TK activity has been observed in solid cancers and hematologic malignancies. Advances in the understanding of the oncogenic activation of TKs led to the identification of new kinase inhibitors with improved potency, specificity, and efficacy. With the advent of imatinib mesylate, a new era in the management of patients with BCR-ABL+ chronic myelogenous leukemia (CML), gastrointestinal stromal tumors, and myeloproliferative neoplasms including chronic myelomonocytic leukemia with PDGFRB gene rearrangements and hypereosinophilic syndrome has begun. CML represents a model for the rational design of TK inhibitors based on the insights into signal transduction pathways. In CML, treatment with imatinib led to an outstanding clinical efficacy with limited toxicity. In BCR-ABL-negative myeloproliferation, the finding of activating point mutations in JAK2 prompted the development of JAK inhibitors to target this activated pathway. Aberrations of epigenetically active genes are the latest finding in the pathogenesis of myeloproliferative disorders and will serve as another target for innovative therapies.

show abstract

Platelet-derived growth factor receptors (PDGFRs) fusion genes involvement in hematological malignancies

Appiah-Kubi

Lan

Wang

et al. 2017

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

The two faces of myeloproliferative neoplasms: Molecular events underlying lymphoid transformation

Cited by 11 publications

References 64 publications

Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes

Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes

Imatinib and Beyond – Targeting Activated Tyrosine Kinases in Myeloproliferative Disorders

Platelet-derived growth factor receptors (PDGFRs) fusion genes involvement in hematological malignancies

Contact Info

Product

Resources

About